A 28-amino-acid peptide naturally produced by the thymus gland that plays a central role in immune system maturation and function. Approved in 35+ countries for hepatitis B and as an immune adjuvant. Used globally as an immune modulator in viral infections and cancer.
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. The thymus gland is where T-cells mature, and Tα1 is one of the key peptides involved in this process.
Marketed as Zadaxin (thymalfasin), Tα1 is approved in over 35 countries for treatment of hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It is notably NOT approved in the United States, despite extensive clinical use internationally. Tα1 gained global attention during COVID-19, where it was used in China and Italy as an immune support in critically ill patients.
Tα1 activates the innate immune system by binding to Toll-like receptors 2 and 9 (TLR2/TLR9) on dendritic cells, stimulating their maturation and antigen-presenting capacity. Mature dendritic cells then activate T-cells more effectively. Tα1 also directly promotes thymocyte maturation into functional T-cells and enhances NK cell cytotoxicity. The net effect is a balanced enhancement of both innate and adaptive immunity.
| Pathway | Effect | Significance |
|---|---|---|
| TLR2/TLR9 activation | Stimulates dendritic cell maturation and cytokine production | Bridges innate and adaptive immunity |
| T-cell maturation | Promotes differentiation of immature thymocytes into functional CD4+ and CD8+ T-cells | Restores T-cell populations in immunocompromised patients |
| NK cell enhancement | Increases NK cell cytotoxicity | Improves innate killing of virus-infected and tumor cells |
| Cytokine modulation | Increases IFN-α, IL-2, IL-12; balances Th1/Th2 response | Promotes antiviral and antitumor immunity without excessive inflammation |
| Anti-inflammatory | Reduces IL-6, TNF-α in hyperinflammatory states | May prevent cytokine storm in severe infections |
| Study | Design | Findings | Level |
|---|---|---|---|
| Hepatitis B | Multiple RCTs, meta-analyses | Improved viral clearance and seroconversion rates when combined with interferon. Basis for approval in 35+ countries | Level I |
| Hepatitis C | RCTs | Enhanced sustained virological response when added to IFN + ribavirin therapy | Level I-II |
| Cancer adjuvant | Multiple trials, various cancers | Improved immune parameters and survival when combined with chemotherapy in melanoma, HCC, lung cancer | Level I-II |
| COVID-19 | Observational + retrospective | Used in China/Italy for critically ill patients. Some studies showed reduced mortality in lymphopenic patients | Level II-III |
| Vaccine adjuvant | Clinical studies | Enhanced antibody responses to influenza and hepatitis B vaccines in elderly and immunocompromised | Level II |
Excellent safety profile: Over 30 years of clinical use with no significant adverse effects reported.
Injection site reactions: Mild injection site redness/swelling occasionally reported.
No immunosuppression: Unlike many immune-modulating drugs, Tα1 does not cause immunosuppression or increase infection risk.
| Jurisdiction | Status |
|---|---|
| FDA | NOT approved in the US. An orphan drug designation was granted but full approval was not pursued. |
| International | Approved in 35+ countries including China, Italy, and many Asian/Latin American countries |
| WHO | Listed as an essential medicine in several countries |
| WADA | Not banned |